| 1 |
33626394 | Short-term standard alcohol consumption enhances platelet response to clopidogrel through inhibition of Nrf2/Ces1 pathway and induction of Cyp2c in mice. | 2021 Aug 15 |
2 |
| 2 |
31039046 | Inhibition of carboxylesterase-1 alters clopidogrel metabolism and disposition. | 2020 Mar |
6 |
| 3 |
33519456 | Physiologically-Based Pharmacokinetic-Pharmacodynamics Model Characterizing CYP2C19 Polymorphisms to Predict Clopidogrel Pharmacokinetics and Its Anti-Platelet Aggregation Effect Following Oral Administration to Coronary Artery Disease Patients With or Without Diabetes. | 2020 |
1 |
| 4 |
29382249 | Methoxsalen as an in vitro phenotyping tool in comparison with 1-aminobenzotriazole. | 2019 Feb |
1 |
| 5 |
30520344 | Prevalence of pharmacogenomic variants affecting the efficacy of clopidogrel therapy in the Hispanic Community Health Study/Study of Latinos cohort. | 2019 Jan |
1 |
| 6 |
30911318 | A Review of Danshen Combined with Clopidogrel in the Treatment of Coronary Heart Disease. | 2019 |
2 |
| 7 |
31175950 | Discovery of natural pentacyclic triterpenoids as potent and selective inhibitors against human carboxylesterase 1. | 2019 Sep |
2 |
| 8 |
31560647 | Effects of the rs2244613 polymorphism of the CES1 gene on the antiplatelet effect of the receptor P2Y12 blocker clopidogrel. | 2019 Sep 27 |
2 |
| 9 |
28990360 | Effects of Genetic Variants on Carboxylesterase 1 Gene Expression, and Clopidogrel Pharmacokinetics and Antiplatelet Effects. | 2018 Mar |
2 |
| 10 |
29240983 | Human UGT2B7 is the major isoform responsible for the glucuronidation of clopidogrel carboxylate. | 2018 Feb |
1 |
| 11 |
27557470 | Identifying clinically relevant sources of variability: The clopidogrel challenge. | 2017 Feb |
1 |
| 12 |
28775293 | Effect of carboxylesterase 1 S75N on clopidogrel therapy among acute coronary syndrome patients. | 2017 Aug 3 |
5 |
| 13 |
26750665 | Gambogic acid potentiates clopidogrel-induced apoptosis and attenuates irinotecan-induced apoptosis through down-regulating human carboxylesterase 1 and -2. | 2016 Sep |
1 |
| 14 |
27196064 | The Metabolism of Clopidogrel: CYP2C19 Is a Minor Pathway. | 2016 Dec |
1 |
| 15 |
27450232 | Impact of genetic polymorphisms related to clopidogrel or acetylsalicylic acid pharmacology on clinical outcome in Chinese patients with symptomatic extracranial or intracranial stenosis. | 2016 Oct |
1 |
| 16 |
28164519 | Angiotensin-Converting Enzyme Inhibitors' Influence on Antiplatelet Therapy of Clopidogrel in ACS. | 2016 Oct 1 |
2 |
| 17 |
25704243 | Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans. | 2015 Jun |
7 |
| 18 |
25747989 | Carboxylesterase 1-mediated drug-drug interactions between clopidogrel and simvastatin. | 2015 |
4 |
| 19 |
25980448 | A population-based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors. | 2015 Oct |
3 |
| 20 |
26767297 | [Computational Pharmacological Study on Clopidogrel Metabolism Enzymes Influenced by Fufang Danshen Dripping Pill]. | 2015 May |
3 |
| 21 |
24535487 | The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease. | 2014 Apr |
1 |
| 22 |
24988246 | The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect. | 2014 |
1 |
| 23 |
25222620 | Clopidogrel bioactivation and risk of bleeding in patients cotreated with angiotensin-converting enzyme inhibitors after myocardial infarction: a proof-of-concept study. | 2014 Dec |
2 |
| 24 |
23111421 | The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. | 2013 Jan |
10 |
| 25 |
23275066 | Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. | 2013 Mar |
15 |
| 26 |
22504157 | Simultaneous absolute protein quantification of carboxylesterases 1 and 2 in human liver tissue fractions using liquid chromatography-tandem mass spectrometry. | 2012 Jul |
1 |
| 27 |
19704027 | A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. | 2009 Nov |
2 |
| 28 |
16943252 | Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. | 2006 Dec |
3 |